Carregant...
Fabrication and Use of PLGA-based Formulations Designed for Modified Release of 5-Fluorouracil
5-fluorouracil (5-FU) is a chemotherapeutic agent that has been used for the treatment of a variety of malignancies since its initial introduction to the clinic in 1957.(1) Due to its short biological half-life, multiple dosings are generally required to maintain effective 5-FU plasma concentrations...
Guardat en:
| Publicat a: | J Pharm Sci |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5768463/ https://ncbi.nlm.nih.gov/pubmed/29045885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xphs.2017.10.012 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|